PDCD1 and non-small cell lung carcinoma: Further, a PDX humanized model for non-small cell lung cancer (NSCLC) has indicated the hCD8 T-cell-mediated efficacy of pembrolizumab (anti-PD-1 antibody) and shown the significant growth inhibitory effect of pembrolizumab on these tumours [51].